Business Context and Reporting Period
This Form 8-K, dated July 31, 2026, reports that Tarsus Pharmaceuticals, Inc. (TARS) entered into a definitive Merger Agreement to acquire Alkeus Pharmaceuticals, Inc. The filing was signed on August 6, 2026. The transaction involves the merger of a Tarsus subsidiary with Alkeus, with Alkeus surviving as a wholly-owned subsidiary of Tarsus.
Key Financial Metrics and Transaction Structure
The acquisition consideration consists of the following components:
- Up-Front Cash Consideration: $270,000,000, subject to customary adjustments and a post-closing purchase price adjustment.
- Up-Front Stock Consideration: $180,000,000 in Tarsus Common Stock, valued at $61.38 per share.
- Milestone Payments: Up to $350,000,000 in aggregate.
- $250,000,000 payable in cash and/or stock upon U.S. regulatory approval of an Alkeus product.
- $100,000,000 payable in cash upon the first U.S. sale of an Alkeus product.
- Revenue Sharing: Tiered payments in the low-to-mid single digits as a percentage of annual worldwide gildeuretinol net sales.
The filing does not provide current revenue, profit, cash flow, or debt metrics for Tarsus Pharmaceuticals, Inc. as this is a transaction announcement rather than a periodic financial report.
Material Changes and Transaction Timeline
The primary material change is the entry into the Merger Agreement. The closing is subject to customary conditions, including the expiration of the Hart-Scott-Rodino waiting period. The transaction is expected to close in 2026. The agreement includes an "Outside Date" of October 31, 2026, which may be extended to January 31, 2027. If the transaction is not consummated by the Outside Date, the agreement may be terminated.
Guidance, Risks, and Contingencies
Contingencies and Conditions:
- Closing is subject to regulatory approvals and customary conditions.
- There is no assurance the acquisition will be consummated on the described terms or at all.
- Milestone payments are contingent upon regulatory approval and first sales.
Registration Rights and Lock-Up:
- Tarsus must file a shelf registration statement for the resale of stock consideration within 30 to 40 days post-closing.
- Alkeus stockholders are subject to a two-month lock-up period on Up-front Stock Consideration following the closing.
- Certain stockholders receiving over $7.0 million in stock consideration face additional selling limitations for three months post-lock-up.
Risks: The filing includes standard forward-looking statement disclaimers, noting that actual results may differ materially due to factors discussed in the Company's Risk Factors section.
Investor Verification Checklist
- Verify the final closing date and whether the October 31, 2026, or January 31, 2027, Outside Date is met.
- Confirm the final purchase price adjustment and the exact number of shares issued for the $180,000,000 stock consideration.
- Monitor the effectiveness of the Initial Resale Shelf registration statement filed by Tarsus.
- Review the full text of the Merger Agreement and exhibits filed in the subsequent Form 10-Q for the quarter ended September 30, 2026.
- Assess the impact of the $270,000,000 cash outlay on Tarsus's current liquidity and cash reserves.